Melanotan II and Growth Hormone: How Their Actions Differ

Melanotan II and human growth hormone are frequently mentioned together because both are injectable peptides sold outside the medical system. Biologically they are unrelated. One acts on pigment-signaling receptors; the other is a hormone that regulates growth and metabolism. Our editorial team explains what each does, their very different regulatory standing in the United States, and the documented safety concerns.

Two unrelated peptides

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone. It was studied in the 1990s as a possible way to stimulate skin pigmentation, but it never completed drug development and has no approved medical use in the United States.

Human growth hormone, or somatotropin, is a natural protein secreted by the pituitary gland. Recombinant growth hormone has been an FDA-approved medicine since 1985 for defined conditions such as childhood and adult growth hormone deficiency, Turner syndrome and some wasting disorders.

So the starting point is a legal and medical gulf. Growth hormone is a prescription biologic with endocrinology guidelines behind it. Melanotan II is an unapproved research chemical that the FDA has warned consumers against buying online.

The two are confused mainly because the underground market sells both as powder in small vials, often alongside marketing claims that have little to do with their real biology.

The biology of melanotan II

Melanotan II binds several melanocortin receptors rather than a single target. Acting on receptors in the skin it can increase production of the dark pigment eumelanin; acting on receptors in the brain it affects appetite and sexual arousal. This lack of selectivity is a central reason it was abandoned as a drug.

Early clinical investigation by Dorr and colleagues confirmed skin darkening in volunteers but also recorded nausea, flushing and other effects. Because the molecule hits many receptors at once, its actions are hard to control, and that is exactly the problem a usable medicine must avoid.

Pharmaceutical development instead moved toward more selective molecules. Afamelanotide, a related but more targeted analog, received FDA approval in 2019 for a rare light-sensitivity disorder. Bremelanotide, from the same research lineage, was approved the same year for a specific sexual-desire disorder in women.

Importantly, melanotan II does not build muscle, does not reliably reduce body fat and has no effect on the growth-hormone system. Any resemblance to performance peptides is a marketing invention, not pharmacology.

The biology of growth hormone

Growth hormone acts on receptors in the liver, muscle, fat and bone. Its best-known effect is prompting the liver to release insulin-like growth factor 1 (IGF-1), which drives tissue growth. It also breaks down stored fat and opposes insulin's action on blood sugar.

In people with a genuine deficiency, physician-supervised replacement can improve body composition, bone density and quality of life, as summarized in Endocrine Society guidance. These benefits are measured against a true medical deficit, not against normal physiology.

In healthy adults the picture is different. Reviews such as that by Liu and colleagues found that growth hormone given to healthy people produced small changes in lean mass and water retention but no proven gains in strength or athletic performance, alongside a clear rise in side effects.

Growth hormone is also tightly regulated in the US beyond the usual prescription rules. Federal law restricts its distribution to approved indications, and non-medical sale is a criminal offense.

Documented safety concerns

For melanotan II, the US FDA and poison-control reports have linked unregulated use to nausea, vomiting, darkening and change of existing moles, and in some reports rhabdomyolysis. Dermatologists have raised particular concern that new or changing pigmented lesions can mask or mimic melanoma, delaying diagnosis.

Because melanotan II is made in unregulated facilities, the actual vial contents, sterility and concentration are unknown. Non-sterile injection carries a real risk of abscess and bloodstream infection regardless of the molecule involved.

For growth hormone, excess exposure is associated with joint pain, fluid retention, carpal tunnel syndrome, insulin resistance and, over the long term, concerns about tissue overgrowth. These effects are dose-related and documented in the medical literature.

• Changing moles or skin lesions warrant prompt dermatology review.
• Persistent joint swelling or numb hands can signal fluid overload from excess GH.
• New or worsening blood-sugar problems deserve medical attention.
• Any unexplained muscle pain with dark urine is a medical emergency.

The honest summary is that neither peptide, used outside medical supervision, has a benefit profile that justifies its risks for a healthy adult seeking physique or performance effects.

Regulatory and anti-doping status

Growth hormone is explicitly prohibited by the World Anti-Doping Agency at all times, in and out of competition, and detection methods exist in elite testing. Athletes who test positive face multi-year bans.

Melanotan II is not primarily a doping agent, but WADA also lists peptide hormones and growth factors broadly, and products of unknown composition can contain prohibited substances. For a tested athlete, an unlabeled vial is a serious contamination risk.

From a consumer-protection standpoint, both substances fall outside the legal supplement framework in the US. They are not dietary supplements and cannot be lawfully sold as such.

Anyone offered either peptide as a shortcut should understand that they are stepping outside both medical supervision and legal supply, with no quality guarantees.

Conclusions of the editorial team

Melanotan II and growth hormone share only the fact that both are injectable peptides sold on the gray market. Their receptors, effects and legal status are entirely different.

Growth hormone is a legitimate medicine for defined deficiencies but offers no proven performance edge in healthy adults and is prohibited in sport. Melanotan II has no approved use and a safety record marked by unpredictable effects and contamination risk.

For a healthy person, the evidence does not support using either one outside a doctor's care.

Readers who want to go deeper may find our pieces on the IGF-1 axis, on how anti-doping testing detects peptide hormones, and on evaluating the safety of injectable products useful next steps.

References

1. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784.
2. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148(10):747–758.
3. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.
4. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: a double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393.
5. World Anti-Doping Agency. The Prohibited List. Peptide hormones, growth factors, related substances and mimetics. Current edition.